- About
- Strategic Plan
- Structure
- Governance
- Scientific divisions
- ACRF Cancer Biology and Stem Cells
- ACRF Chemical Biology
- Advanced Technology and Biology
- Bioinformatics
- Blood Cells and Blood Cancer
- Clinical Translation
- Epigenetics and Development
- Immunology
- Infectious Diseases and Immune Defence
- Inflammation
- Personalised Oncology
- Population Health and Immunity
- Structural Biology
- Ubiquitin Signalling
- Laboratory operations
- Funding
- Annual reports
- Human research ethics
- Scientific integrity
- Institute life
- Career opportunities
- Business Development
- Partnering opportunities
- A complete cure for HBV
- A stable efficacious Toxoplasma vaccine
- Activating SMCHD1 to treat FSHD
- Improving vision outcomes in retinal detachment
- Intercepting inflammation with RIPK2 inhibitors
- Novel inhibitors for the treatment of lupus
- Novel malaria vaccine
- Precision epigenetics silencing SMCHD1 to treat Prader Willi Syndrome
- Rethinking CD52 a therapy for autoimmune disease
- Targeting minor class splicing
- Royalties distribution
- Start-up companies
- Partnering opportunities
- Collaborators
- Publications repository
- Awards
- Discoveries
- Centenary 2015
- History
- Contact us
- Research
- Diseases
- Cancer
- Development and ageing
- Immune health and infection
- Research fields
- Research technologies
- People
- Anne-Laure Puaux
- Associate Profesor Ian Majewski
- Associate Professor Aaron Jex
- Associate Professor Alyssa Barry
- Associate Professor Andrew Webb
- Associate Professor Chris Tonkin
- Associate Professor Daniel Gray
- Associate Professor Diana Hansen
- Associate Professor Edwin Hawkins
- Associate Professor Emma Josefsson
- Associate Professor Ethan Goddard-Borger
- Associate Professor Grant Dewson
- Associate Professor Isabelle Lucet
- Associate Professor James Murphy
- Associate Professor James Vince
- Associate Professor Jason Tye-Din
- Associate Professor Jeanne Tie
- Associate Professor Jeff Babon
- Associate Professor Joan Heath
- Associate Professor Justin Boddey
- Associate Professor Kate Sutherland
- Associate Professor Leanne Robinson
- Associate Professor Marco Herold Marco Herold
- Associate Professor Marie-Liesse Asselin-Labat
- Associate Professor Matthew Ritchie
- Associate Professor Melissa Davis
- Associate Professor Misty Jenkins
- Associate Professor Nawaf Yassi
- Associate Professor Oliver Sieber
- Associate Professor Peter Czabotar
- Associate Professor Rachel Wong
- Associate Professor Rhys Allan
- Associate Professor Rosie Watson
- Associate Professor Ruth Kluck
- Associate Professor Sandra Nicholson
- Associate Professor Sant-Rayn Pasricha
- Associate Professor Seth Masters
- Associate Professor Sumitra Ananda
- Associate Professor Tim Thomas
- Associate Professor Wai-Hong Tham
- Associate Professor Wei Shi
- Catherine Parker
- Chela Niall
- Deborah Carr
- Dr Alisa Glukhova
- Dr Anna Coussens
- Dr Ashley Ng
- Dr Ben Tran
- Dr Bernhard Lechtenberg
- Dr Brad Sleebs
- Dr Drew Berry
- Dr Gemma Kelly
- Dr Gwo Yaw Ho
- Dr Hui-Li Wong
- Dr Jacqui Gulbis
- Dr Joanna Groom
- Dr John Wentworth
- Dr Kelly Rogers
- Dr Lucy Gately
- Dr Margaret Lee
- Dr Mary Ann Anderson
- Dr Maryam Rashidi
- Dr Matthew Call
- Dr Melissa Call
- Dr Philippe Bouillet
- Dr Rebecca Feltham
- Dr Samir Taoudi
- Dr Shalin Naik
- Dr Sheau Wen Lok
- Dr Simon Chatfield
- Dr Tracy Putoczki
- Guillaume Lessene
- Helene Martin
- Joh Kirby
- Kaye Wycherley
- Keely Bumsted O'Brien
- Mr Joel Chibert
- Mr Simon Monard
- Mr Steve Droste
- Ms Carolyn MacDonald
- Professor Alan Cowman
- Professor Andreas Strasser
- Professor Andrew Lew
- Professor Andrew Roberts
- Professor Anne Voss
- Professor Clare Scott
- Professor David Huang
- Professor David Komander
- Professor David Vaux
- Professor Doug Hilton
- Professor Gabrielle Belz
- Professor Geoff Lindeman
- Professor Gordon Smyth
- Professor Ian Wicks
- Professor Ivo Mueller
- Professor Jane Visvader
- Professor Jerry Adams
- Professor John Silke
- Professor Ken Shortman
- Professor Leonard C Harrison
- Professor Lynn Corcoran
- Professor Marc Pellegrini
- Professor Marnie Blewitt
- Professor Melanie Bahlo
- Professor Mike Lawrence
- Professor Nicos Nicola
- Professor Peter Colman
- Professor Peter Gibbs
- Professor Phil Hodgkin
- Professor Stephen Nutt
- Professor Suzanne Cory
- Professor Terry Speed
- Professor Tony Burgess
- Professor Tony Papenfuss
- Professor Warren Alexander
- Diseases
- Education
- PhD
- Honours
- Masters
- Undergraduate
- Student research projects
- A new regulator of stemness to create dendritic cell factories for immunotherapy
- Advanced methods for genomic rearrangement detection
- Control of cytokine signaling by SOCS1
- Defining the protein modifications associated with respiratory disease
- Delineating the pathways driving cancer development and therapy resistance
- Developing a new drug that targets plasmacytoid dendritic cells for the treatment of lupus
- Development and mechanism of action of novel antimalarials
- Development of a novel particle-based malaria vaccine
- Development of tau-specific therapeutic and diagnostic antibodies
- Discovering novel therapies for major human pathogens
- Dissecting host cell invasion by the diarrhoeal pathogen Cryptosporidium
- Epigenetic biomarkers of tuberculosis infection
- Essential role of glycobiology in malaria parasites
- Evolution of haematopoiesis in vertebrates
- Human lung protective immunity to tuberculosis
- Identifying novel treatment options for ovarian carcinosarcoma
- Interaction with Toxoplasma parasites and the brain
- Interactions between tumour cells and their microenvironment in non-small cell lung cancer
- Investigating the role of mutant p53 in cancer
- Microbiome strain-level analysis using long read sequencing
- Minimising rheumatic adverse events of checkpoint inhibitor cancer therapy
- Modelling spatial and demographic heterogeneity of malaria transmission risk
- Naturally acquired immune response to malaria parasites
- Predicting the effect of non-coding structural variants in cancer
- Structural basis of catenin-independent Wnt signalling
- Structure and biology of proteins essential for Toxoplasma parasite invasion
- T lymphocytes: how memories are made
- TICKER: A cell history recorder for longitudinal patient monitoring
- Targeting host pathways to develop new broad-spectrum antiviral drugs
- Targeting post-translational modifications to disrupting the function of secreted proteins
- Targeting the epigenome to rewire pro-allergic T cells
- Targeting the immune microenvironment to treat KRAS-mutant adenocarcinoma
- The E3 ubiquitin ligase Parkin and mitophagy in Parkinson’s disease
- The molecular controls on dendritic cell development
- Understanding malaria infection dynamics
- Understanding the genetics of neutrophil maturation
- Understanding the neuroimmune regulation of innate immunity
- Understanding the proteins that regulate programmed cell death at the molecular level
- Using cutting-edge single cell tools to understand the origins of cancer
- When healthy cells turn bad: how immune responses can transition to lymphoma
- School resources
- Frequently asked questions
- Student profiles
- Abebe Fola
- Andrew Baldi
- Anna Gabrielyan
- Bridget Dorizzi
- Casey Ah-Cann
- Catia Pierotti
- Emma Nolan
- Huon Wong
- Jing Deng
- Joy Liu
- Kaiseal Sarson-Lawrence
- Komal Patel
- Lilly Backshell
- Megan Kent
- Naomi Jones
- Rebecca Delconte
- Roberto Bonelli
- Rune Larsen
- Runyu Mao
- Sarah Garner
- Simona Seizova
- Wayne Cawthorne
- Wil Lehmann
- Miles Horton
- Alexandra Gurzau
- Student achievements
- Student association
- News
- Donate
- Online donation
- Ways to support
- Support outcomes
- Supporter stories
- Rotarians against breast cancer
- A partnership to improve treatments for cancer patients
- 20 years of cancer research support from the Helpman family
- A generous gift from a cancer survivor
- A gift to support excellence in Australian medical research
- An enduring friendship
- Anonymous donor helps bridge the 'valley of death'
- Renewed support for HIV eradication project
- Searching for solutions to muscular dystrophy
- Supporting research into better treatments for colon cancer
- Taking a single cell focus with the DROP-seq
- WEHI.TV
Medicinal chemistry

Developing new medicines is an important aspect of our disease research. Our medicinal chemistry team is working to improve the treatment of many significant diseases.
Our medicinal chemistry research
Our medicinal chemistry researchers aim to develop new medications to treat a variety of diseases including:
- Cancer
- Malaria
- Inflammatory diseases such as rheumatoid arthritis
- Neurodegeneration
- Ischaemic and reperfusion injuries, which occur when the blood supply to a tissue is lost, and then reestablished such as occurs in in heart attack and stroke.
Our medicinal chemistry team works closely with many other researchers at the institute to advance the development of new treatments for disease, and to understand how diseases develop.
What is medicinal chemistry?
Medicinal chemistry refers to the discovery, design and production of new medicines.
Medicinal chemistry combines:
- Biological understanding of the key proteins and processes contributing to a disease.
- Organic chemistry knowledge to design, develop and synthesise the compounds that alter the disease-causing molecules.
- Understanding how the body interacts with, and metabolises, small molecules, to obtain molecules that can be used as potential medicines.
What makes a medicine?
Many diseases can be traced to changes in how certain molecules, often proteins, function within cells. In many diseases, differences in cell signalling pathways exist between diseased cells and normal cells.
Targeted therapies are medicines that interact with a specific biological molecule, usually a protein. Targeted therapies can:
- Stop a molecule from working, called inhibition, or
- Encourage a molecule to work, called activation.
Many targeted therapies are ‘small molecules’, indicating the chemical’s size is much smaller than important biological molecules such as proteins or DNA.
There are many steps between finding a small molecule, or compound, that changes how a protein works, and it being available to treat people with a particular disease. Important features of potential medicines include:
- Stability, so the compound does not rapidly degrade before it can be used.
- Chemical properties including solubility and cell permeability, meaning the compound can travel through the body to diseased cells, and enter the cells.
- Specificity, meaning that the compound does not influence other molecules unrelated to the disease.
When small molecules are developed that have the potential to treat disease, they must undergo rigorous testing before they enter clinical use. The processes of pre-clinical testing and clinical trials are explained on our Clinical Translation page.
From structure to medicine
Knowing the three dimensional shape, or structure of a protein can give important clues about how it can be altered by a medicine. Our medicinal chemists work closely with structural biology researchers to develop new medications targeted to a specific part of a protein related to disease.
High throughput screening
One of the most efficient methods of discovering new compounds that modify protein or cell behaviour is through the screening of large and diverse collections of small molecules. From this ‘chemical library’, small molecules that have the appropriate effect can be identified.
Chemical libraries can contain hundreds of thousands of distinct small molecules. These must each be tested in a consistent way to detect those compounds that have the desired effect.
In screening a chemical library it is important to include:
- A rapid screening method that allows screening of the entire library in a time-efficient way.
- A reliable readout that maximises the chance that a compound with the desired effect can be discovered, but minimises the chance of a ‘false positive’ compound that is wrongly detected despite not having the desired effect.
High throughput technology and powerful computing methods for analysing experimental data are important elements of screening.
Often, the small molecules discovered to have the desired effect may not have the best properties of a medicine. Medicinal chemists can make further chemical modifications to design a candidate new medication that is similar to the small molecule but has better stability, solubility and specificity.
Chemical biology
Medicinal chemistry aims to develop new compounds that treat certain diseases, but the processes used can also advance other research into those diseases.
Chemical biology develops and uses small molecules to precisely inhibit a specific protein or biological process. This can be invaluable to research into that molecule or process, and lead to a better understanding of how certain diseases develop. Chemical biology approaches can complement other research fields such as genetics, cell biology and molecular biology, to understand a biological process.
In the long run, some small molecules produced by chemical biology research can be the basis of new medications.
Researchers:
Super Content:
The NDDC enables medical researchers to access ultra-high throughput screening, fast tracking scientific discoveries into new medicines.
The institute's malaria research team is homing in on a new target for malaria treatment
Professor Andrew Roberts discusses the results of a clinical trial of a potential new anti-cancer agent on ABC Radio.
Collaborative research has led to a new compound that blocks a protein linked to poor responses to treatment in cancer patients
Professor Geoff Lindeman discusses his team's findings